The 42-employee biotech firm managed to raise capital despite a slowdown in venture dollars flowing to startups in today’s uncertain economic environment. They are involved in neuro-immune over-activation, which can occur in many chronic disorders, causing swelling, pain, itching and other problems. The company is currently focused on two drug candidates in its pipeline. The second therapy candidate targets chronic spontaneous urticaria, chronic inducible urticaria and atopic dermatitis — which involve hives, welts, swelling, pain and itching that are linked to various conditions. The company expects to begin a Phase 1 study on this second therapy in early 2023.

Source: thestar December 02, 2022 14:38 UTC